OBIZUR
STN: BL 125512
Proper Name: Antihemophilic Factor (Recombinant), Porcine Sequence
Tradename: OBIZUR
Manufacturer: Baxter Healthcare Corporation
Indication:
- Treatment and control of bleeding episodes in adults with acquired hemophilia A.
On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.